Non small cell lung cancer management: Difference between revisions
No edit summary |
|||
(8 intermediate revisions by 3 users not shown) | |||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The optimal management approach of non-small cell lung cancer will depend on a series of characteristics, that include: pre-treatment evaluation, location, and adequate staging. | The optimal management approach of non-small cell lung cancer will depend on a series of characteristics, that include: pre-treatment evaluation, location, and adequate [[Cancer staging|staging]]. Common treatment options for management of non-small cell lung cancer include [[surgery]], [[neoadjuvant chemotherapy]], [[Adjuvant therapy|adjuvant chemotherapy]], and [[radiation therapy]]. | ||
==Management Approach== | ==Management Approach== | ||
*The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer | *The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer.<ref name="PDQ"> PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016 </ref> <small>To have a detailed information on the sequential management please click on each TNM stage in the table.</small> | ||
{|style="border: 5px; font-size: 90%; margin: 5px; width: 1000px" align=center | {| style="border: 5px; font-size: 90%; margin: 5px; width: 1000px" align="center" | ||
!style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="3"|{{fontcolor|#FFF|'''Standard Treatment Options'''<br><SMALL>Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016) <ref name="PDQ"> PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016 </ref></SMALL>}} | ! style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="3" |{{fontcolor|#FFF|'''Standard Treatment Options'''<br><SMALL>Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016) <ref name="PDQ"> PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016 </ref></SMALL>}} | ||
|+ | |+ | ||
|- | |- | ||
Line 17: | Line 17: | ||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|'''Standard Treatment Options'''}} | ! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|'''Standard Treatment Options'''}} | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| ''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage I|Stages IA and IB]]''' | ||
| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|style="padding: 5px 5px; background: #F5F5F5;"| | |||
*Surgery | *Surgery | ||
*Radiation therapy | *Radiation therapy | ||
*IB, if the tumor is >4cm, surgery and chemotherapy | *IB, if the tumor is >4cm, surgery and chemotherapy | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|'''Stages IIA and IIB''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Non small cell lung cancer medical therapy stage II|Stages IIA and IIB]]''' | ||
|style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Surgery | *Surgery | ||
*Neoadjuvant chemotherapy | *Neoadjuvant chemotherapy | ||
Line 39: | Line 30: | ||
*Radiation therapy | *Radiation therapy | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage IIIA''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage III|Stage IIIA]]''' | ||
|style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
'''Resected or resectable disease''' | '''Resected or resectable disease''' | ||
*Surgery | *Surgery | ||
Line 59: | Line 50: | ||
*Chemotherapy combined with radiation therapy and/or surgery | *Chemotherapy combined with radiation therapy and/or surgery | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage IIIB''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage III|Stage IIIB]]''' | ||
|style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Sequential or concurrent chemotherapy and radiation therapy | *Sequential or concurrent chemotherapy and radiation therapy | ||
*Chemotherapy followed by surgery (for selected patients) | *Chemotherapy followed by surgery (for selected patients) | ||
*Radiation therapy alone | *Radiation therapy alone | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage IV''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage IV|Stage IV]]''' | ||
|style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Cytotoxic combination chemotherapy (first line) | *Cytotoxic combination chemotherapy (first line) | ||
*Combination chemotherapy with bevacizumab or cetuximab | *Combination chemotherapy with bevacizumab or cetuximab | ||
Line 76: | Line 67: | ||
* External-beam radiation therapy (primarily for palliation of local symptomatic tumor growth) | * External-beam radiation therapy (primarily for palliation of local symptomatic tumor growth) | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Recurrent''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''Recurrent''' | ||
|style="padding: 5px 5px; background: #F5F5F5;"| | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Radiation therapy (for palliation) | *Radiation therapy (for palliation) | ||
*Chemotherapy or kinase inhibitors alone EGFR inhibitors in patients with/without EGFR mutations | *Chemotherapy or kinase inhibitors alone EGFR inhibitors in patients with/without EGFR mutations | ||
Line 93: | Line 84: | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Lung cancer]] | [[Category:Lung cancer]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Pulmonology]] | |||
[[Category:Surgery]] |
Latest revision as of 22:22, 23 February 2018
Non Small Cell Lung Cancer Microchapters |
Differentiating Non Small Cell Lung Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Non small cell lung cancer management On the Web |
American Roentgen Ray Society Images of Non small cell lung cancer management |
Directions to Hospitals Treating Non small cell carcinoma of the lung |
Risk calculators and risk factors for Non small cell lung cancer management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
The optimal management approach of non-small cell lung cancer will depend on a series of characteristics, that include: pre-treatment evaluation, location, and adequate staging. Common treatment options for management of non-small cell lung cancer include surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiation therapy.
Management Approach
- The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer.[1] To have a detailed information on the sequential management please click on each TNM stage in the table.
Standard Treatment Options Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016) [1] |
||
---|---|---|
Stage (TNM criteria) | Standard Treatment Options | |
Stages IA and IB |
| |
Stages IIA and IIB |
| |
Stage IIIA |
Resected or resectable disease
Unresectable disease
Superior sulcus tumors
Tumors that invade the chest wall
| |
Stage IIIB |
| |
Stage IV |
Maintenance therapy following first-line chemotherapy
| |
Recurrent |
|
References
- ↑ 1.0 1.1 PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016